This is simple. You can give real money to regenerative medicine without it costing you a dime. JPMorgan Chase & Co’s Chase Community Giving program is giving away $5 million to the charities with the most votes. Your vote could mean money for regenerative medicine.
Don’t be silly. Just click here and [...]

No tags Hide

This may seem a little off-topic for those who don’t know me but for those of you who do, you’ll know this is a little mix of many of my primary loves – cell therapy/regenerative medicine, communications/public relations, social media, and all things internet/technology.
This is a reprint (with permission) of an article I was invited [...]

No tags Hide

Stewart Lyman of Lyman BioPharma Consulting posted a great article in today’s Xconomy summarizing some key points and links to more information about the rules governing the Therapeutic Discovery Project Credit which have now been released by the US Treasury Department. Today, a detailed fact sheet was released about the tax credit program [...]

No tags Hide

While the US government prints money to shore up failing and broken business models which no one likes but are considered simply too big (not too important or significant or even useful) to fail, Google is making money and investing it in start ups who expect nothing less than to create “disruptive, even world-changing technologies”.
No [...]

No tags Hide

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It’s here. Dendreon has brought Provenge to market. Here, in the word’s of the FDA…
FDA NEWS RELEASE
For Immediate Release: April 29, 2010
FDA Approves a Cellular Immunotherapy for [...]

No tags Hide

I know I haven’t been a very good blogger for quite some time but I wanted to pass on a letter I just received from my friend James Price as a Charter member of the Canadian Stem Cell Foundation. They’re going for a Webby award. You don’t have to be Canadian to support [...]

No tags Hide

It has been pointed out to me by legal counsel that the 25 July 2008 letter from the FDA to Regenerative Sciences, Inc regarding what FDA observed as apparent “violations” of FDA regulation by Regenexx, was not a “Warning Letter” as that term is officially defined but rather an “Untitled Letter” which has less or [...]

No tags Hide

As Late, Late Show host, Craig Ferguson, says…”It’s a great day for America. ‘Why is it a great day for America,’ you ask? Well, let me tell you”.

The US House of Representatives has passed what promises to be (if approved by the Senate) the largest single budget increase for the FDA in the [...]

No tags Hide

I apologize for the quality of this image but hopefully its just clear enough for you to make out this week’s Genetic Engineering News poll. If you’re reading this in realtime you will see on GEN’s homepage.

In case you can’t read it, the poll is this:
“Which type of stem cells will be the [...]

No tags Hide

Let’s get the public services announcement out of the way right up front.

CellTherapy 2010. Save the date. Submit your session ideas. www.celltherapy2010.com

While you’re planning your calendar, plan on the 2009 World Stem Cell Summit September 21-23, 2009. Baltimore Convention Center Baltiomore, Maryland. (the 2008 World Stem Cell Summit webcast and downloadable World Stem Cell [...]

No tags Hide

Last week I mentioned the Regenerative Medicine Foundation and the conference they have announced for Spring 2010. I promised to find out more and bring you what I learned.

I’ve discovered that the driver behind the RMF is Anthony Atala and Case Western. It is a 501(c)(3) charity, non-profit organization. It was formed [...]

No tags Hide

I don’t have much time to give you an extensive blog about the issue but I did want to bring this to your attention. Here’s the nutshell.
The NIH’s SBIR (Small Business Innovation Research Program) funding mechanism has been an important one for small businesses who are not big/mature/saavy/desperate-enough to land venture capital funding, have [...]

No tags Hide

“Autologous manufacturing is not the deal breaker it used to be. If these [cell-based] vaccines work for really difficult-to-treat diseases, the manufacturing issues will be worked out.” Howard Liang, MBA, Ph.D., Analyst and Biotechnology Managing Direct at Leerink Swan. “Special Report: Customized Cancer Vaccines Finally (Maybe) Arrive“. GEN News Highlights. [...]

No tags Hide

I’m always skeptical of companies or products or technologies that depend on a ‘paradigm-shift’ or ’sea-change’ in the long-entrenched habits of people before they will be widely adopted and/or successful.

It’s why, for example alternative fuel autos might succeed in the U.S. where public transit has not – because they don’t require as big a [...]

No tags Hide

…this is a continuation of Part I…

So are Personalized Medicines the Long Tail of the Therapeutics Industry?
In 2006, Chris Anderson, Editor-in-Chief of Wired magazine, released “The Long Tail” – a book describing the Web 2.0-induced business-to-consumer economics (r)evolution enabling businesses to now deliver product at outrageously affordable prices to global micro-markets.[i] The book quickly became [...]

No tags Hide

This week I’m ROTFLMAO loving this cartoon so I thought I’d share the chuckles (thanks to www.onstartups.com). I can’t tell you how many times in the past years I’ve seen the inevitable ‘hockey stick’ market projections graph from companies, analysts, and investors when discussing the coming 5 years in the cell therapy sector. [...]

No tags Hide

I’m back.
That on the left my friends is the new squawking reason I’ve been quite on the blogosphere and Twitter scene for the past few weeks!
I know this issue of my Industry HiLites has some rather stale news but it also has some recent news. What I can’t promise is that I’ve captured all [...]

No tags Hide

Here is a listing of the corporate tutorial and symposia sessions being held at the International Society for Cellular Therapy conference Sunday-Wednesday in San Diego. For more information see www.celltherapy.org.

ISCT 2009 Corporate Tutorial and Symposium Listing

[...]

No tags Hide

Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company’s investigational active cellular immunotherapy for the treatment [...]

No tags Hide

Here we are in April 2009. The much newly anticipated date when we expect the Dendreon saga to head toward a climax. Few people know the Dendreon story better then Xconomy journalist, Luke Timmerman who does an outstanding job of summarizing the saga and stakes in Dendreon’s immiment Provenge gamble. Indeed tomorrow is the [...]

No tags Hide